Bright Minds Biosciences, Inc. (DRUG)
66.53
-0.38
(-0.57%)
USD |
NASDAQ |
Sep 09, 10:52
Bright Minds Biosciences Enterprise Value : 443.08M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | 443.08M |
| September 04, 2026 | 425.82M |
| September 03, 2026 | 454.03M |
| September 02, 2026 | 484.61M |
| September 01, 2026 | 481.85M |
| August 31, 2026 | 490.63M |
| August 28, 2026 | 501.28M |
| August 27, 2026 | 518.30M |
| August 26, 2026 | 538.96M |
| August 25, 2026 | 567.17M |
| August 24, 2026 | 542.86M |
| August 21, 2026 | 546.75M |
| August 20, 2026 | 558.00M |
| August 19, 2026 | 618.96M |
| August 18, 2026 | 612.05M |
| August 17, 2026 | 567.07M |
| August 14, 2026 | 537.09M |
| August 13, 2026 | 552.47M |
| August 12, 2026 | 565.99M |
| August 11, 2026 | 574.67M |
| August 10, 2026 | 580.00M |
| August 07, 2026 | 565.59M |
| August 06, 2026 | 580.09M |
| August 05, 2026 | 572.20M |
| August 04, 2026 | 546.06M |
| Date | Value |
|---|---|
| August 03, 2026 | 510.85M |
| July 31, 2026 | 505.72M |
| July 30, 2026 | 519.23M |
| July 29, 2026 | 484.02M |
| July 28, 2026 | 492.90M |
| July 27, 2026 | 492.40M |
| July 24, 2026 | 486.68M |
| July 23, 2026 | 486.29M |
| July 22, 2026 | 527.42M |
| July 21, 2026 | 545.47M |
| July 20, 2026 | 519.04M |
| July 17, 2026 | 533.93M |
| July 16, 2026 | 515.29M |
| July 15, 2026 | 531.96M |
| July 14, 2026 | 513.31M |
| July 13, 2026 | 532.06M |
| July 10, 2026 | 550.90M |
| July 09, 2026 | 554.45M |
| July 08, 2026 | 472.38M |
| July 07, 2026 | 420.69M |
| July 06, 2026 | 440.52M |
| July 02, 2026 | 449.89M |
| July 01, 2026 | 439.43M |
| June 30, 2026 | 475.53M |
| June 29, 2026 | 456.95M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 581.29M |
| Amgen, Inc. | 255.86B |
| Anika Therapeutics, Inc. | 268.42M |
| BioCryst Pharmaceuticals, Inc. | 2.798B |
| Imunon, Inc. | 8.166M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.732M |
| Total Expenses (Quarterly) | 1.732M |
| EPS Diluted (Quarterly) | -0.1762 |
| Earnings Yield | -3.13% |
| Normalized Earnings Yield | -3.133 |